OmniAb, Inc. (OABI)
$4.70-1.47%Close
BUYBEAR · day 3
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $560M
- Beta
- 1.05
- P/E (TTM)
- -13.06
- Short % float
- 6.94%
- Days to cover
- 6.8
- SI change
- +15.1%
- 1W
- +8.05%
- 1M
- +4.91%
- vs SPY 1W
- +8.18%
- vs SPY 1M
- +2.40%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 0
- VALUE
- 0
- GROWTH
- 12
- GARP
- 4
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-10.0%
REV YoY-
ROE-16.6%
EPS YoY-
ROA-15.2%
GROSS51
OP-126
NET-115
[VALUATION]
P/E TTM-13.06
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B2.33
P/FCF-
EV/EBITDA-33.75
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E7.27
ALTMAN Z-
CURR RATIO4.80
ND/EBITDA-
BETA1.05
Company news
FAQ
- What is LOPJLB’s current signal on OABI?
- LOPJLB’s latest quantitative signal on OmniAb, Inc. (OABI) is BUY in a BEAR regime. Signals are updated daily.
- What market regime is OABI in?
- OmniAb, Inc. (OABI) is currently classified in the BEAR HMM market regime on LOPJLB.
- What does OmniAb, Inc. (OABI) do?
- OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capabi…